Keywords: novo, levormeloxifene, enters, phase, iii, nordisk, completed

Novo's Levormeloxifene Enters Phase III

Article | 27 November 1997

Novo Nordisk has completed Phase II studies of levormeloxifene, aselective estrogen receptor modulator in development for the prevention of osteoporosis, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Novo Nordisk

Lilly

Go to company listing

Related Drugs

Evista

Raloxifene

Go to drug listing